Oncology: Mutation testing for lung cancer completed prior to start of targeted therapy - ICD-10-CM Quality Payment Program Measure
Quality Measure | Description | High Priority | Submission Methods |
---|---|---|---|
Oncology: Mutation testing for lung cancer completed prior to start of targeted therapy | Proportion of stage 4 NSCLC patients tested for actionable biomarkers, including EGFR, BRAF mutation; ROS1, ALK rearrangement; PD-L1 expression, and received targeted therapy or chemotherapy based on biomarker results. | YES | Registry |
Linked ICD-10 Codes
The following ICD-10-CM codes are linked to the quality measure oncology: mutation testing for lung cancer completed prior to start of targeted therapy when used as part of a patient's medical record. This Quality Measure is part of Medicare's Quality Payment Program (QPP).
ICD Code | Description | Category |
---|